HPV-negative head and neck squamous cell carcinoma (HNSCC) is the classical form of head and neck cancer, strongly associated with tobacco and alcohol use. It is genetically characterized by TP53 mutations (greater than 80%), CDKN2A inactivation, and frequent EGFR amplification or overexpression. HPV-negative HNSCC has a worse prognosis than HPV-positive disease, with 5-year survival rates of 40-50% for locally advanced tumors. The disease commonly affects the oral cavity, larynx, and hypopharynx.
Ask a research question about HPV-Negative Head and Neck Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: HPV-Negative Head and Neck Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-04-22T20:13:21Z'
description: >-
HPV-negative head and neck squamous cell carcinoma (HNSCC) is the classical form
of head and neck cancer, strongly associated with tobacco and alcohol use. It is
genetically characterized by TP53 mutations (greater than 80%), CDKN2A inactivation,
and frequent EGFR amplification or overexpression. HPV-negative HNSCC has a worse
prognosis than HPV-positive disease, with 5-year survival rates of 40-50% for
locally advanced tumors. The disease commonly affects the oral cavity, larynx,
and hypopharynx.
categories:
- Head and Neck Cancer
- Environmental Cancer
- Tobacco-Related Cancer
parents:
- head and neck squamous cell carcinoma
has_subtypes:
- name: Oral Cavity Squamous Cell Carcinoma
description: >-
Carcinoma arising from the mucosal lining of the oral cavity including
the lips, buccal mucosa, floor of mouth, oral tongue, hard palate, and
retromolar trigone. Strongly associated with tobacco and alcohol.
- name: Laryngeal Squamous Cell Carcinoma
description: >-
Carcinoma of the larynx (voice box) affecting the glottic, supraglottic,
or subglottic regions. Smoking is the dominant risk factor. Presents
early with hoarseness when affecting the vocal cords.
- name: Hypopharyngeal Squamous Cell Carcinoma
description: >-
Carcinoma of the hypopharynx (lower throat), including pyriform sinuses,
posterior pharyngeal wall, and postcricoid region. Often presents at
advanced stage with poor prognosis.
environmental:
- name: Tobacco Smoking
description: >-
Cigarette smoking is the dominant risk factor for HPV-negative HNSCC,
with a dose-response relationship. Tobacco smoke contains numerous
carcinogens including polycyclic aromatic hydrocarbons and nitrosamines
that cause DNA adducts and mutations, particularly in TP53.
evidence:
- reference: PMID:36414699
reference_title: "[The tumor microenvironment-relay station for prognosis and therapy response]."
supports: PARTIAL
snippet: "Besides tobacco and alcohol abuse, human papilloma virus (HPV) infection is an independent risk factor, particularly in oropharyngeal squamous cell carcinomas (OPSCC)."
explanation: "Identifies tobacco (and alcohol) as major risk factors for HNSCC."
exposure_term:
preferred_term: exposure to tobacco smoking
term:
id: ECTO:6000029
label: exposure to tobacco smoking
- name: Alcohol Consumption
description: >-
Chronic alcohol consumption synergizes with tobacco to increase HNSCC
risk multiplicatively. Alcohol acts as a solvent enhancing carcinogen
penetration and is metabolized to acetaldehyde, a DNA-damaging agent.
Ethanol is classified as a Group 1 carcinogen by IARC.
evidence:
- reference: PMID:39244563
reference_title: "Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study."
supports: SUPPORT
snippet: "Smoking and alcohol independently increase the risk of both HPV-positive and HPV-negative HNSCC."
explanation: "Abstract reports alcohol increases risk for HPV-negative HNSCC."
exposure_term:
preferred_term: exposure to ethanol
term:
id: ECTO:9000027
label: exposure to ethanol
pathophysiology:
- name: TP53 Mutation and Inactivation
description: >-
TP53 mutations occur in greater than 80% of HPV-negative HNSCC, representing
the most common genetic alteration. Mutations are typically missense
mutations in the DNA-binding domain caused by tobacco carcinogen-induced
DNA adducts. Loss of p53 function eliminates cell cycle checkpoints
and DNA damage repair.
evidence:
- reference: PMID:25631445
reference_title: "Comprehensive genomic characterization of head and neck squamous cell carcinomas."
supports: SUPPORT
snippet: "Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 mutations and CDKN2A inactivation"
explanation: "TCGA HNSCC abstract reports near-universal TP53 loss and CDKN2A inactivation in smoking-related tumors."
cell_types:
- preferred_term: squamous epithelial cell
term:
id: CL:0000076
label: squamous epithelial cell
biological_processes:
- preferred_term: cell cycle checkpoint signaling
modifier: DECREASED
term:
id: GO:0000075
label: cell cycle checkpoint signaling
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
genes:
- preferred_term: TP53
term:
id: hgnc:11998
label: TP53
downstream:
- target: Genomic Instability
description: Loss of p53-mediated DNA damage response leads to accumulated mutations
- name: CDKN2A/p16 Inactivation
description: >-
CDKN2A is inactivated by deletion, mutation, or promoter hypermethylation
in approximately 60-70% of HPV-negative HNSCC. Loss of p16INK4a removes
inhibition of CDK4/6, promoting cell cycle progression through the
restriction point.
genes:
- preferred_term: CDKN2A
term:
id: hgnc:1787
label: CDKN2A
biological_processes:
- preferred_term: negative regulation of G1/S transition
modifier: DECREASED
term:
id: GO:2000134
label: negative regulation of G1/S transition of mitotic cell cycle
downstream:
- target: Cell Cycle Dysregulation
description: CDK4/6 phosphorylates pRB without restraint
- name: EGFR Overexpression and Signaling
description: >-
EGFR is overexpressed in 80-90% of HNSCC and amplified in a subset.
EGFR signaling activates RAS-MAPK and PI3K-AKT pathways, promoting
proliferation, survival, and invasion. EGFR is a validated therapeutic
target in HNSCC.
biological_processes:
- preferred_term: epidermal growth factor receptor signaling pathway
modifier: INCREASED
term:
id: GO:0007173
label: epidermal growth factor receptor signaling pathway
downstream:
- target: RAS-MAPK Activation
description: EGFR phosphorylation activates RAS and downstream MAP kinases
- target: PI3K-AKT Activation
description: EGFR recruits PI3K and activates survival signaling
- name: NOTCH1 Inactivation
description: >-
NOTCH1 loss-of-function mutations occur in approximately 15-20% of
HPV-negative HNSCC. NOTCH signaling normally promotes squamous
differentiation and growth arrest, functioning as a tumor suppressor
in squamous epithelia.
genes:
- preferred_term: NOTCH1
term:
id: hgnc:7881
label: NOTCH1
biological_processes:
- preferred_term: Notch signaling pathway
modifier: DECREASED
term:
id: GO:0007219
label: Notch signaling pathway
histopathology:
- name: Squamous Cell Carcinoma
finding_term:
preferred_term: Squamous Cell Carcinoma
term:
id: NCIT:C2929
label: Squamous Cell Carcinoma
frequency: VERY_FREQUENT
description: Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.
evidence:
- reference: PMID:36414699
reference_title: "[The tumor microenvironment-relay station for prognosis and therapy response]."
supports: PARTIAL
snippet: "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer"
explanation: Abstract explicitly names head and neck squamous cell carcinoma.
phenotypes:
- category: Head and Neck
name: Oral Lesion
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Non-healing ulcers, white or red patches (leukoplakia, erythroplakia),
or masses in the oral cavity may represent primary tumors or precursor
lesions.
phenotype_term:
preferred_term: Oral ulcer
term:
id: HP:0000155
label: Oral ulcer
- category: Head and Neck
name: Neck Mass
frequency: VERY_FREQUENT
description: >-
Cervical lymphadenopathy from nodal metastases is common at presentation.
May be the presenting symptom, particularly for hypopharyngeal tumors.
phenotype_term:
preferred_term: Lymphadenopathy
term:
id: HP:0002716
label: Lymphadenopathy
- category: Head and Neck
name: Dysphagia
frequency: FREQUENT
description: >-
Difficulty swallowing occurs with tumors of the tongue, oropharynx,
hypopharynx, or any location causing obstruction.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
- category: Head and Neck
name: Hoarseness
frequency: FREQUENT
description: >-
Voice changes are characteristic of laryngeal carcinoma and an early
symptom when the tumor involves the true vocal cords.
phenotype_term:
preferred_term: Hoarse voice
term:
id: HP:0001609
label: Hoarse voice
- category: Head and Neck
name: Odynophagia
frequency: FREQUENT
description: >-
Painful swallowing occurs with ulcerative lesions or deep invasion
of the pharyngeal mucosa.
phenotype_term:
preferred_term: Odynophagia
term:
id: HP:0032043
label: Odynophagia
- category: Constitutional
name: Weight Loss
frequency: FREQUENT
description: >-
Unintentional weight loss is common due to dysphagia, pain, and
catabolic effects of cancer. May indicate advanced disease.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Ear
name: Otalgia
frequency: OCCASIONAL
description: >-
Referred ear pain (via cranial nerves IX and X) may occur with
pharyngeal and laryngeal tumors despite a normal ear examination.
phenotype_term:
preferred_term: Otalgia
term:
id: HP:0030766
label: Ear pain
biochemical:
- name: p16 Immunohistochemistry
notes: >-
Unlike HPV-positive HNSCC, p16 is typically negative or focally/weakly
positive in HPV-negative tumors due to CDKN2A inactivation. p16 status
is critical for staging oropharyngeal carcinoma in the 8th edition AJCC
staging system.
- name: EGFR Expression
notes: >-
EGFR overexpression is common but has not proven useful as a predictive
biomarker for cetuximab response. EGFR gene copy number and mutations
are less common than overexpression.
genetic:
- name: TP53
association: Somatic Mutations
notes: >-
TP53 mutations occur in greater than 80% of HPV-negative HNSCC. Mutation
spectrum shows tobacco carcinogen signature with G-to-T transversions.
TP53 mutation is associated with worse prognosis and treatment resistance.
- name: CDKN2A
association: Deletion/Methylation
notes: >-
CDKN2A is inactivated in 60-70% of HPV-negative HNSCC through homozygous
deletion, promoter hypermethylation, or point mutation.
- name: PIK3CA
association: Somatic Mutations
notes: >-
PIK3CA activating mutations occur in approximately 10-15% of HPV-negative
HNSCC, activating PI3K/AKT/mTOR signaling.
- name: NOTCH1
association: Loss-of-Function Mutations
notes: >-
NOTCH1 inactivating mutations occur in 15-20% of cases, impairing
squamous differentiation.
- name: EGFR
association: Amplification/Overexpression
notes: >-
EGFR is overexpressed in 80-90% of HNSCC and amplified in approximately
15%. Provides rationale for EGFR-targeted therapy.
treatments:
- name: Surgical Resection
description: >-
Primary surgery is preferred for oral cavity cancers and selected
laryngeal/pharyngeal tumors. Extent depends on tumor stage and location.
Reconstruction may be required for adequate margins.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Definitive Chemoradiation
description: >-
Concurrent cisplatin-based chemotherapy with radiation therapy is
standard for locally advanced laryngeal, hypopharyngeal, and oropharyngeal
cancers where organ preservation is desired.
treatment_term:
preferred_term: radiation therapy
term:
id: MAXO:0000014
label: radiation therapy
therapeutic_agent:
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- name: Cetuximab
description: >-
EGFR monoclonal antibody approved in combination with radiation for
locally advanced disease and with chemotherapy for recurrent/metastatic
disease. Alternative to cisplatin in patients unable to tolerate platinum.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: cetuximab
term:
id: NCIT:C1723
label: Cetuximab
- name: Immunotherapy
description: >-
PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent
or metastatic HNSCC as monotherapy or with chemotherapy. Response
rates are modest (approximately 15-20% monotherapy).
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
disease_term:
preferred_term: head and neck squamous cell carcinoma
term:
id: MONDO:0010150
label: head and neck squamous cell carcinoma
classifications:
icdo_morphology:
classification_value: Squamous Cell Carcinoma
harrisons_chapter:
- classification_value: cancer
- classification_value: solid tumor
references:
- reference: DOI:10.1002/ame2.12367
title: Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck squamous cell cancer (HNSCC) is a leading global malignancy.
supporting_text: Head and neck squamous cell cancer (HNSCC) is a leading global malignancy.
evidence:
- reference: DOI:10.1002/ame2.12367
reference_title: Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Head and neck squamous cell cancer (HNSCC) is a leading global malignancy.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1002/jmv.29746
title: 'Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high‐risk human papillomavirus (HR HPV), notably HPV16 and HPV18.
supporting_text: Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high‐risk human papillomavirus (HR HPV), notably HPV16 and HPV18.
evidence:
- reference: DOI:10.1002/jmv.29746
reference_title: 'Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high‐risk human papillomavirus (HR HPV), notably HPV16 and HPV18.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1002/mc.23640
title: Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancer
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck squamous cell carcinomas (HNSCC) remain a poorly understood disease clinically and immunologically.
supporting_text: Head and neck squamous cell carcinomas (HNSCC) remain a poorly understood disease clinically and immunologically.
evidence:
- reference: DOI:10.1002/mc.23640
reference_title: Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancer
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Head and neck squamous cell carcinomas (HNSCC) remain a poorly understood disease clinically and immunologically.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1007/s10147-024-02632-x
title: 'First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: 'First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048'
supporting_text: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
evidence:
- reference: DOI:10.1007/s10147-024-02632-x
reference_title: 'First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1007/s12105-024-01680-z
title: Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas
supporting_text: Our aim was to assess the ability of simultaneous immunohistochemical staining (IHC) for p16 and p53 to accurately subclassify head and neck squamous cell carcinomas (HNSCC) as HPV-associated (HPV-A) versus HPV-independent (HPV-I) and compare p53 IHC staining patterns to TP53 mutation status, p16 IHC positivity and HPV status.
evidence:
- reference: DOI:10.1007/s12105-024-01680-z
reference_title: Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas
supports: SUPPORT
evidence_source: OTHER
snippet: Our aim was to assess the ability of simultaneous immunohistochemical staining (IHC) for p16 and p53 to accurately subclassify head and neck squamous cell carcinomas (HNSCC) as HPV-associated (HPV-A) versus HPV-independent (HPV-I) and compare p53 IHC staining patterns to TP53 mutation status, p16 IHC positivity and HPV status.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1016/j.heliyon.2024.e40671
title: 'Health-related quality of life assessment in head and neck cancer: A systematic review of phase II and III clinical trials'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: 'Health-related quality of life assessment in head and neck cancer: A systematic review of phase II and III clinical trials'
supporting_text: 'Health-related quality of life assessment in head and neck cancer: A systematic review of phase II and III clinical trials'
- reference: DOI:10.1016/j.isci.2024.109282
title: Global burden of head and neck cancers from 1990 to 2019
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Global burden of head and neck cancers from 1990 to 2019
supporting_text: Global burden of head and neck cancers from 1990 to 2019
- reference: DOI:10.1038/s41388-023-02783-7
title: Genetically engineered mouse models of head and neck cancers
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: The head and neck region is one of the anatomic sites commonly afflicted by cancer, with ~1.5 million new diagnoses reported worldwide in 2020 alone.
supporting_text: The head and neck region is one of the anatomic sites commonly afflicted by cancer, with ~1.5 million new diagnoses reported worldwide in 2020 alone.
evidence:
- reference: DOI:10.1038/s41388-023-02783-7
reference_title: Genetically engineered mouse models of head and neck cancers
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: The head and neck region is one of the anatomic sites commonly afflicted by cancer, with ~1.5 million new diagnoses reported worldwide in 2020 alone.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1038/s41416-023-02186-1
title: Preclinical models in head and neck squamous cell carcinoma
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck cancer is the sixth most frequent cancer type.
supporting_text: Head and neck cancer is the sixth most frequent cancer type.
evidence:
- reference: DOI:10.1038/s41416-023-02186-1
reference_title: Preclinical models in head and neck squamous cell carcinoma
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Head and neck cancer is the sixth most frequent cancer type.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1038/s41467-024-53390-3
title: Hallmarks of a genomically distinct subclass of head and neck cancer
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs).
supporting_text: Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs).
evidence:
- reference: DOI:10.1038/s41467-024-53390-3
reference_title: Hallmarks of a genomically distinct subclass of head and neck cancer
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs).
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1038/s41467-024-55203-z
title: Molecular correlates for HPV-negative head and neck cancer engraftment prognosticate patient outcomes
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Molecular correlates for HPV-negative head and neck cancer engraftment prognosticate patient outcomes
supporting_text: Molecular correlates for HPV-negative head and neck cancer engraftment prognosticate patient outcomes
- reference: DOI:10.1038/s41571-024-00904-z
title: 'Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: 'Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination'
supporting_text: 'Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination'
- reference: DOI:10.1158/1535-7163.mct-24-0281
title: 'Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Despite notable progress in the treatment of advanced head and neck squamous cell carcinoma (HNSCC), survival remains poor in patients with recurrent and/or metastatic (R/M) human papillomavirus (HPV)–negative HNSCC.
supporting_text: Despite notable progress in the treatment of advanced head and neck squamous cell carcinoma (HNSCC), survival remains poor in patients with recurrent and/or metastatic (R/M) human papillomavirus (HPV)–negative HNSCC.
evidence:
- reference: DOI:10.1158/1535-7163.mct-24-0281
reference_title: 'Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Despite notable progress in the treatment of advanced head and neck squamous cell carcinoma (HNSCC), survival remains poor in patients with recurrent and/or metastatic (R/M) human papillomavirus (HPV)–negative HNSCC.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1186/s12885-024-12155-3
title: 'Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen.
supporting_text: The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen.
evidence:
- reference: DOI:10.1186/s12885-024-12155-3
reference_title: 'Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1186/s12929-023-00953-z
title: 'Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and Neck cancers (HNC) are a heterogeneous group of upper aero-digestive tract cancer and account for 931,922 new cases and 467,125 deaths worldwide.
supporting_text: Head and Neck cancers (HNC) are a heterogeneous group of upper aero-digestive tract cancer and account for 931,922 new cases and 467,125 deaths worldwide.
evidence:
- reference: DOI:10.1186/s12929-023-00953-z
reference_title: 'Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Head and Neck cancers (HNC) are a heterogeneous group of upper aero-digestive tract cancer and account for 931,922 new cases and 467,125 deaths worldwide.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1186/s13027-024-00592-5
title: A SEER-based analysis of trends in HPV-associated oropharyngeal squamous cell carcinoma
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
supporting_text: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
evidence:
- reference: DOI:10.1186/s13027-024-00592-5
reference_title: A SEER-based analysis of trends in HPV-associated oropharyngeal squamous cell carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1186/s41199-020-00056-4
title: Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Comprehensive molecular characterization of head and neck squamous cell carcinoma (HNSCC) has led to the identification of distinct molecular subgroups with fundamental differences in biological properties and clinical behavior.
supporting_text: Comprehensive molecular characterization of head and neck squamous cell carcinoma (HNSCC) has led to the identification of distinct molecular subgroups with fundamental differences in biological properties and clinical behavior.
evidence:
- reference: DOI:10.1186/s41199-020-00056-4
reference_title: Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Comprehensive molecular characterization of head and neck squamous cell carcinoma (HNSCC) has led to the identification of distinct molecular subgroups with fundamental differences in biological properties and clinical behavior.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.1200/jco.21.02508
title: 'Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048.
supporting_text: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048.
evidence:
- reference: DOI:10.1200/jco.21.02508
reference_title: 'Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.2196/47579
title: 'Cause of Death in Patients with Oropharyngeal Carcinoma by Human Papillomavirus Status: Comparative Data Analysis'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: The incidence of oropharyngeal squamous cell carcinomas (OPSCC) has increased in recent decades, and human papillomavirus (HPV) infection is the main cause of OPSCC.
supporting_text: The incidence of oropharyngeal squamous cell carcinomas (OPSCC) has increased in recent decades, and human papillomavirus (HPV) infection is the main cause of OPSCC.
evidence:
- reference: DOI:10.2196/47579
reference_title: 'Cause of Death in Patients with Oropharyngeal Carcinoma by Human Papillomavirus Status: Comparative Data Analysis'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The incidence of oropharyngeal squamous cell carcinomas (OPSCC) has increased in recent decades, and human papillomavirus (HPV) infection is the main cause of OPSCC.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.32481/djph.2023.04.008
title: Human Papilloma Virus (HPV) and the Current State of Oropharyngeal Cancer Prevention and Treatment
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Human Papilloma Virus (HPV) and the Current State of Oropharyngeal Cancer Prevention and Treatment
supporting_text: Human Papilloma Virus (HPV) and the Current State of Oropharyngeal Cancer Prevention and Treatment
- reference: DOI:10.3389/fonc.2023.1160144
title: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
supporting_text: Pembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy.
evidence:
- reference: DOI:10.3389/fonc.2023.1160144
reference_title: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Pembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.3390/cancers15030656
title: Accuracy of p16 IHC in Classifying HPV-Driven OPSCC in Different Populations
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: High-risk human papillomavirus (HPV) infection is a defined etiopathogenetic factor in oropharyngeal carcinogenesis with a clear prognostic value.
supporting_text: High-risk human papillomavirus (HPV) infection is a defined etiopathogenetic factor in oropharyngeal carcinogenesis with a clear prognostic value.
evidence:
- reference: DOI:10.3390/cancers15030656
reference_title: Accuracy of p16 IHC in Classifying HPV-Driven OPSCC in Different Populations
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: High-risk human papillomavirus (HPV) infection is a defined etiopathogenetic factor in oropharyngeal carcinogenesis with a clear prognostic value.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.3390/cancers15164080
title: 'Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
supporting_text: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
evidence:
- reference: DOI:10.3390/cancers15164080
reference_title: 'Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.3390/diagnostics14131448
title: 'The Role of Biomarkers in HPV-Positive Head and Neck Squamous Cell Carcinoma: Towards Precision Medicine'
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck cancer (HNC) represents a significant global health challenge, with squamous cell carcinomas (SCCs) accounting for approximately 90% of all HNC cases.
supporting_text: Head and neck cancer (HNC) represents a significant global health challenge, with squamous cell carcinomas (SCCs) accounting for approximately 90% of all HNC cases.
evidence:
- reference: DOI:10.3390/diagnostics14131448
reference_title: 'The Role of Biomarkers in HPV-Positive Head and Neck Squamous Cell Carcinoma: Towards Precision Medicine'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Head and neck cancer (HNC) represents a significant global health challenge, with squamous cell carcinomas (SCCs) accounting for approximately 90% of all HNC cases.
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
- reference: DOI:10.34172/jcs.33282
title: Dysphagia, Voice Problems and Health Related Quality of Life Among Head and Neck Cancer Survivors
found_in:
- HPV_Negative_Head_and_Neck_Cancer-deep-research-falcon.md
findings:
- statement: Head and neck cancer (HNC) and its treatment can cause significant side effects like dysphagia, voice problems which can affect health related quality of life (HRQOL).
supporting_text: Head and neck cancer (HNC) and its treatment can cause significant side effects like dysphagia, voice problems which can affect health related quality of life (HRQOL).
evidence:
- reference: DOI:10.34172/jcs.33282
reference_title: Dysphagia, Voice Problems and Health Related Quality of Life Among Head and Neck Cancer Survivors
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Head and neck cancer (HNC) and its treatment can cause significant side effects like dysphagia, voice problems which can affect health related quality of life (HRQOL).
explanation: Deep research cited this publication as relevant literature for HPV Negative Head and Neck Cancer.
| Field | Value |
|---|---|
| Preferred name | HPV-negative head and neck squamous cell carcinoma (HPV-negative HNSCC) (krsek2024theroleof pages 14-15, tasoulas2023geneticallyengineeredmouse pages 1-2) |
| Common synonyms | HPV− HNSCC; HPV-negative HNSCC; HPV-independent HNSCC; HPV-unrelated HNSCC; tobacco/alcohol-associated HNSCC (context-dependent); for oropharyngeal disease: HPV-negative OPSCC, p16-negative OPSCC, HPV-independent OPSCC (krsek2024theroleof pages 14-15, pakkanen2024simultaneousp53and pages 1-2, gallus2023accuracyofp16 pages 1-2, tran2024advancesinhuman pages 6-7) |
| Disease family | Head and neck squamous cell carcinoma (HNSCC), a squamous malignancy of the upper aerodigestive tract (tasoulas2023geneticallyengineeredmouse pages 1-2, xie2024immunelandscapein pages 1-2) |
| Typical anatomic subsites | Oral cavity, larynx, hypopharynx, and oropharynx; HNSCC arises from mucosal epithelium lining the oral cavity, pharynx, and larynx (tasoulas2023geneticallyengineeredmouse pages 1-2, xie2024immunelandscapein pages 1-2) |
| Oropharyngeal-specific terminology | In OPSCC, current classification distinguishes HPV-associated vs HPV-independent disease; p16 IHC is widely used as a surrogate marker, but p16-positive/HPV-negative discordance occurs, so confirmatory HPV nucleic-acid testing may be needed in selected cases (gallus2023accuracyofp16 pages 4-5, gallus2023accuracyofp16 pages 2-4, gallus2023accuracyofp16 pages 1-2, tran2024advancesinhuman pages 6-7) |
| Key classification note | WHO/AJCC framework separates HPV-associated OPSCC from HPV-independent/HPV-negative OPSCC because they are clinically and molecularly distinct entities with different prognosis (krsek2024theroleof pages 14-15, gallus2023accuracyofp16 pages 1-2) |
| p16 IHC note | p16 immunohistochemistry is an accepted practical surrogate for HPV-associated OPSCC, typically positive when >70% of tumor cells show strong nuclear and cytoplasmic staining; p16-negative OPSCC generally supports HPV-independent disease, but p16 alone is imperfect (pakkanen2024simultaneousp53and pages 1-2, gallus2023accuracyofp16 pages 1-2, tran2024advancesinhuman pages 6-7) |
| Distinguishing biology | HPV-negative disease is commonly linked to tobacco/alcohol exposure and frequently shows TP53 and CDKN2A alterations, unlike HPV-positive disease driven by viral E6/E7 biology (krsek2024theroleof pages 14-15, tasoulas2023geneticallyengineeredmouse pages 1-2) |
| MONDO ID | Not established from retrieved evidence; placeholder: MONDO: [not available from retrieved evidence] |
| MeSH | Placeholder: MeSH term for disease subset [not available from retrieved evidence]; broader family term HNSCC/head and neck neoplasms used in literature (tasoulas2023geneticallyengineeredmouse pages 1-2, xie2024immunelandscapein pages 1-2) |
| ICD-10 / ICD-11 | No single retrieved code specific to HPV-negative HNSCC subset; use site-specific head and neck SCC coding plus HPV-status modifiers where available; placeholder: ICD-10/11 [site-specific / not available from retrieved evidence] |
| Evidence source type | Aggregated disease-level literature and classification/guideline-style reviews, not individual EHR-derived records (krsek2024theroleof pages 14-15, tasoulas2023geneticallyengineeredmouse pages 1-2, gallus2023accuracyofp16 pages 1-2) |
Table: This table summarizes practical names, synonyms, anatomic scope, and classification notes for HPV-negative head and neck squamous cell carcinoma. It is useful for harmonizing ontology mapping and terminology in a disease knowledge base when specific MONDO/MeSH/ICD identifiers are not directly available from the retrieved evidence.
HPV− HNSCC refers to head and neck squamous cell carcinomas that are not driven by transcriptionally active high-risk HPV and are typically associated with carcinogen exposure (notably tobacco and alcohol), with a molecular landscape dominated by tumor-suppressor loss and high genomic instability (krsek2024theroleof pages 14-15, tasoulas2023geneticallyengineeredmouse pages 1-2, park2024advancedhumanpapillomavirus–negative pages 1-2).
In oropharyngeal squamous cell carcinoma (OPSCC), HPV-associated and HPV-independent disease are now treated as clinically distinct entities because of differences in prognosis and biology; p16 immunohistochemistry (IHC) is widely used as a practical surrogate for HPV association but is imperfect (gallus2023accuracyofp16 pages 1-2, tran2024advancesinhuman pages 6-7).
This report is based on aggregated disease-level resources (primary trials, registry studies, systematic reviews, translational studies), not individual EHR-only data (harrington2023pembrolizumabwithor pages 1-2, zhang2023causeofdeath pages 1-2, waas2024molecularcorrelatesfor pages 1-2).
Carcinogen-associated etiology dominates HPV− disease. Across HNSCC, tobacco and alcohol are repeatedly identified as major etiologic drivers, and HPV− tumors are enriched among patients with these exposures (krsek2024theroleof pages 14-15, xie2024immunelandscapein pages 1-2).
A 2023 review summarizing global burden states that “at least 75% of HNSCCs are attributable to tobacco smoking and alcohol consumption” and that combined heavy use confers a markedly increased risk (reported as 35-fold higher risk) (huang2023circulatingtumourdna pages 1-2).
Other risk factors referenced in recent reviews include betel nut chewing and low socioeconomic status (tasoulas2023geneticallyengineeredmouse pages 1-2).
While the provided evidence does not include a formal G×E model, it links tobacco-associated carcinogenesis to: - high mutational burden and copy-number alterations (CNAs) in HPV− tumors (park2024advancedhumanpapillomavirus–negative pages 1-2, huang2023circulatingtumourdna pages 4-6) - loss of cell-cycle regulators and immunologic features consistent with an immunosuppressive/hypoxic tumor microenvironment (TME) (park2024advancedhumanpapillomavirus–negative pages 1-2).
A 2024 head and neck cancer survivor cohort (n=110) provides subsite and stage distributions: oral cavity 52.7%, oropharyngeal/nasopharyngeal 20.0%, pharyngeal 16.4%, larynx/hypopharynx 10.9%; stage III 32.7% and stage IV 27.3% (sharma2024dysphagiavoiceproblems pages 2-3). Although HPV status was not specified, these subsites and late-stage distributions are consistent with populations heavily enriched for HPV− disease in many settings.
Post-treatment and survivorship phenotypes are prominent and clinically important: - Dysphagia (HPO: HP:0002015) (sharma2024dysphagiavoiceproblems pages 1-2) - Voice impairment / hoarseness (HPO: HP:0001609 Dysphonia) (sharma2024dysphagiavoiceproblems pages 1-2) - Pain (HPO: HP:0012531) (filippini2024healthrelatedqualityof pages 1-2) - Xerostomia (HPO: HP:0000217) (filippini2024healthrelatedqualityof pages 1-2) - Weight loss / malnutrition (HPO: HP:0001824 Weight loss; HP:0004395 Malnutrition) (filippini2024healthrelatedqualityof pages 1-2)
A 2024 survivor cohort reported very high prevalence of functional sequelae: - Dysphagia in 85.5% (94/110) - Severe voice problems in 50% (sharma2024dysphagiavoiceproblems pages 1-2, sharma2024dysphagiavoiceproblems pages 2-3)
In the same cohort, EORTC QLQ-C30 functional scores were relatively high for cognitive functioning (mean 80.76) and role functioning (80.30), while symptoms included pain (mean 42.42), fatigue (42.22), and financial difficulties (41.21) (sharma2024dysphagiavoiceproblems pages 1-2).
A 2024 systematic review of phase II/III trials emphasized dysphagia and speech problems as long-term burdens: dysphagia/dysarthria were described as affecting ~50% within the first year post-radiotherapy with persistence in subsets for years, and treatment-associated weight loss (>5%) occurs in 66% during therapy (filippini2024healthrelatedqualityof pages 1-2).
(UBERON IDs are standard ontology suggestions; not explicitly enumerated in the retrieved papers.)
HPV− HNSCC is characterized by frequent tumor suppressor alterations and extensive CNAs (park2024advancedhumanpapillomavirus–negative pages 1-2, huang2023circulatingtumourdna pages 4-6).
A 2024 expert review focusing on advanced HPV− HNSCC reports mutation/alteration frequencies: - TP53 altered ~84% - CDKN2A altered ~58% - CCND1 altered ~31% - PIK3CA altered ~34% and recurrent focal deletions including NSD1, FAT1, NOTCH1, SMAD4 (park2024advancedhumanpapillomavirus–negative pages 1-2).
A ctDNA-focused 2023 review similarly emphasizes TP53 dominance and notes TP53 mutations in 73–100% of HPV− HNSCC in cited series, plus recurrent alterations impacting CCND1/CDKN2A, FAT1 (Wnt signaling activation), NOTCH pathway, EGFR CNV, and NRF2 pathway (smoking-associated) (huang2023circulatingtumourdna pages 4-6).
A 2024 Nature Communications study identifies a distinct HPV− oral cavity SCC subgroup with no/few CNAs (“CNA-quiet”) comprising 73/802 (9.1%), enriched for wild-type TP53 and frequent CASP8/HRAS mutations, with a less immunosuppressed TME (lower regulatory T-cell density) and improved survival compared with CNA-other tumors (muijlwijk2024hallmarksofa pages 1-2).
A 2024 transcriptomic immune deconvolution analysis across >700 HPV− HNSCC cases assigns HPV− tumors into four molecular subtypes (classical, basal, mesenchymal, atypical) and reports: - Atypical and mesenchymal subtypes show greater immune enrichment and T-cell exhaustion phenotypes relative to classical and basal - distinct B-cell maturation/isotype patterns - a hypothesis that treatments enhancing B-cell activity may benefit atypical subtypes (xie2024immunelandscapein pages 1-2, xie2024immunelandscapein pages 2-3).
Key pathways and processes inferred from the evidence: - Cell-cycle dysregulation (GO:0007049 cell cycle) via TP53/CDKN2A loss, CCND1 gain (park2024advancedhumanpapillomavirus–negative pages 1-2) - DNA damage response / genomic instability (GO:0006974 cellular response to DNA damage stimulus) (huang2023circulatingtumourdna pages 4-6) - EGFR/PI3K/AKT signaling (GO:0014066 regulation of phosphatidylinositol 3-kinase signaling; GO:0045744 negative regulation of G1/S transition) (park2024advancedhumanpapillomavirus–negative pages 1-2, huang2023circulatingtumourdna pages 4-6) - Hypoxia response (GO:0001666 response to hypoxia) and immune suppression in tobacco-associated HPV− tumors (park2024advancedhumanpapillomavirus–negative pages 1-2)
(Cell Ontology IDs are standard ontology suggestions; not explicitly enumerated in the retrieved papers.)
The strongest evidence-supported modifiable drivers for HPV− HNSCC remain: - Tobacco exposure - Alcohol exposure with synergy increasing risk substantially (huang2023circulatingtumourdna pages 1-2).
A consistent mechanistic model supported by recent reviews is: 1) Carcinogen exposure (tobacco/alcohol) → 2) DNA damage and mutagenesis → 3) Loss of tumor suppressor control and cell-cycle checkpoint failure (TP53, CDKN2A; CCND1 gains) → 4) CNA accumulation and pathway rewiring (EGFR/PI3K signaling; Wnt/NOTCH disruption; NRF2 oxidative stress response) → 5) Immune evasion / hypoxic noninflamed TME in many tumors → 6) Invasion/metastasis and therapy resistance (park2024advancedhumanpapillomavirus–negative pages 1-2, huang2023circulatingtumourdna pages 4-6).
A 2024 HPV−-focused therapeutic review attributes worse outcomes partly to a “noninflamed and hypoxic tumor microenvironment” and reduced immune activation, including fewer CD8+ T cells and suppressed interferon pathway signals in tobacco-associated HPV− tumors (park2024advancedhumanpapillomavirus–negative pages 1-2).
Primary sites are the mucosal epithelium of the oral cavity, pharynx (including oropharynx), larynx, and hypopharynx (tasoulas2023geneticallyengineeredmouse pages 1-2, xie2024immunelandscapein pages 1-2). Complications and functional impacts reflect involvement of swallowing and voice structures in the upper aerodigestive tract (filippini2024healthrelatedqualityof pages 1-2, sharma2024dysphagiavoiceproblems pages 1-2).
HPV− HNSCC commonly presents in older patients and is frequently diagnosed at advanced stages in many settings (krsek2024theroleof pages 14-15, park2024advancedhumanpapillomavirus–negative pages 1-2). The clinical course varies by subsite and stage; survivorship can be characterized by prolonged functional impairment (dysphagia, xerostomia, speech/voice problems) especially after radiotherapy (filippini2024healthrelatedqualityof pages 1-2).
OPSCC staging has distinct HPV-associated vs HPV-independent rules under AJCC/UICC 8th edition; p16 status is incorporated into staging for OPSCC because of prognostic separation (gallus2023accuracyofp16 pages 1-2, tran2024advancesinhuman pages 6-7).
HPV− HNSCC is not typically a monogenic inherited disorder; it is best modeled as multifactorial (environmental carcinogens + somatic evolution). No germline inheritance pattern is supported by the provided evidence.
A guideline-aligned approach in the evidence base is: 1) p16 IHC as initial screening for OPSCC/selected HNSCC contexts, with p16 positivity defined as >70% of tumor cells showing moderate-to-strong nuclear and cytoplasmic staining (tran2024advancesinhuman pages 6-7). 2) Confirmatory nucleic-acid testing when clinical decisions depend on HPV-driven status (e.g., de-intensification or staging certainty), using DNA ISH/PCR or (preferably for transcriptional activity) RNA ISH targeting E6/E7 mRNA (tran2024advancesinhuman pages 6-7, gallus2023accuracyofp16 pages 2-4).
p16 is sensitive but not fully specific. A 2024 review reported p16 overexpression in 93.2% of HPV-positive OPSCC but also 18.8% of HPV-negative patients; another cited series found 24% p16 positivity in HPV16-negative tumors, suggesting non-HPV causes of p16 upregulation (e.g., inflammation/regeneration or p53-related biology) (tran2024advancesinhuman pages 6-6).
A 2023 analysis emphasizes that p16 false-positive rates depend on HPV prevalence in the tested population and warns that p16+/HPV− tumors can have prognosis similar to p16− tumors; thus confirmatory HPV nucleic-acid testing is recommended, especially in low-prevalence settings (gallus2023accuracyofp16 pages 1-2).
Table-based evidence of false-positive rates across populations and assays is shown in Table 1 from Gallus et al. (cropped table images) (gallus2023accuracyofp16 media 97554451, gallus2023accuracyofp16 media 6b48023a, gallus2023accuracyofp16 media 4f7617b0).
A 2024 Head & Neck Pathology study proposes combined p16 and p53 IHC to classify HNSCC as: - HPV-associated (HPV-A): p16+/p53 wildtype - HPV-independent (HPV-I): p16−/p53 abnormal (“mutant pattern”)
In their cohort (n=31), 28/31 were straightforward; discordant cases were resolved with molecular testing. Adding p53 IHC increased the positive predictive value (PPV) of p16 positivity for HPV-A from 91.7% to 100%; HPV-associated p53 patterns showed specificity 100% with sensitivity 83% (pakkanen2024simultaneousp53and pages 1-2, pakkanen2024simultaneousp53and pages 5-6).
ctDNA is discussed as a biomarker for prognosis and surveillance in HNSCC due to tumor heterogeneity and sampling limitations; the cited review provides global burden and emphasizes the need for alternative sampling strategies, but does not provide HPV−-specific validated ctDNA thresholds in the excerpt (huang2023circulatingtumourdna pages 1-2).
HPV− OPSCC and HPV− HNSCC overall show substantially worse outcomes than HPV-associated disease, with strong population-level evidence.
| Evidence type/cohort | HPV-negative outcome metric | Comparator (if any) | Key quantitative results | Notes | URL/DOI |
|---|---|---|---|---|---|
| SEER OPSCC cohort, stage I-IVB, 2010-2015 (n=5,852) (zhang2023causeofdeath pages 1-2) | Cause-specific and competing mortality in HPV-negative OPSCC | HPV-positive OPSCC | 5-year head-and-neck cancer-specific mortality: 26.9% vs 10.7%; second primary cancer mortality: 12.4% vs 4.6%; non-cancer mortality: 13.7% vs 5.8%; HPV positivity associated with lower subdistribution hazards for HNCSM (sHR 0.362, 95% CI 0.315-0.417), SPCM (0.400, 0.321-0.496), NCCM (0.460, 0.378-0.560) (zhang2023causeofdeath pages 1-2) | Strong population-level evidence that HPV-negative OPSCC has substantially worse disease-specific and competing-cause outcomes than HPV-positive disease | https://doi.org/10.2196/47579 |
| General clinical prognosis in HPV-negative R/M HNSCC review (park2024advancedhumanpapillomavirus–negative pages 1-2) | Overall survival in advanced/recurrent disease | Not directly compared in same metric; contrasted conceptually with HPV-positive disease | Review states median OS for HPV-negative R/M HNSCC is approximately 1 year, and approximately 6 months after progression on PD-1/chemotherapy-based therapy (park2024advancedhumanpapillomavirus–negative pages 1-2) | Expert review frames HPV-negative disease as an unmet-need population with poorer outcomes partly related to tumor-suppressor loss and a noninflamed, hypoxic TME | https://doi.org/10.1158/1535-7163.MCT-24-0281 |
| Nature Communications biomarker study in HPV-negative HNSCC with PDX engraftment workflow; 273 resected specimens, molecular profiling subset n=88, validation cohort n=404 (waas2024molecularcorrelatesfor pages 1-2) | Prognostic biomarkers LAMC2 and TGM3 | Risk stratification beyond nodal status alone | Cohort disease-specific survival at 3 years was 71% overall; engraftment correlated with worse outcomes and adverse features including N category (p=0.022), surgical margin (p=0.037), and nodal extracapsular extension (p=0.038); LAMC2/TGM3 significantly improved prediction beyond nodal status alone (waas2024molecularcorrelatesfor pages 1-2) | Biomarker-based prognostication may identify poor-risk HPV-negative patients even among node-negative cases; translational relevance from engraftment phenotype | https://doi.org/10.1038/s41467-024-55203-z |
| Nature Communications multicenter OCSCC cohort; HPV-negative oral cavity SCC, n=802 (muijlwijk2024hallmarksofa pages 1-2) | Prognosis of CNA-quiet HPV-negative subclass | CNA-other HPV-negative OCSCC | 73/802 (9.1%) tumors were CNA-quiet; this subgroup had better 5-year overall survival than CNA-other tumors, with wild-type TP53, frequent CASP8/HRAS mutations, and lower regulatory T-cell density (muijlwijk2024hallmarksofa pages 1-2) | Identifies a favorable-prognosis biologic subset within otherwise generally poor-prognosis HPV-negative disease; also more common in older patients, women, and fewer current smokers | https://doi.org/10.1038/s41467-024-53390-3 |
| Molecular subtype immune-landscape analysis across >700 HPV-negative HNSCC patients (3 cohorts) (xie2024immunelandscapein pages 1-2, xie2024immunelandscapein pages 2-3) | Outcome heterogeneity within HPV-negative HNSCC | Internal comparison across HPV-negative molecular subtypes | Atypical and mesenchymal subtypes showed greater immune enrichment and T-cell exhaustion than classical/basal subtypes; study supports biologically distinct risk groups within HPV-negative disease, though no single pooled survival percentage is given in the excerpt (xie2024immunelandscapein pages 1-2, xie2024immunelandscapein pages 2-3) | Useful for prognosis refinement and future precision immunotherapy design in HPV-negative HNSCC | https://doi.org/10.1002/mc.23640 |
| Comparative prognosis statements from biomarker/review literature (krsek2024theroleof pages 14-15, xie2024immunelandscapein pages 1-2, tran2024advancesinhuman pages 2-3, tran2024advancesinhuman pages 2-2) | Overall and progression-free survival tendency in HPV-negative disease | HPV-positive HNSCC/OPSCC | Multiple reviews state HPV-positive tumors have higher OS/PFS and better radiosensitivity, whereas HPV-negative tumors are more heterogeneous and have worse outcomes; one cited comparison reported 3-year OS 57.1% in HPV-negative vs 82.4% in HPV-positive disease (tran2024advancesinhuman pages 2-3) | Broad consensus across recent literature that HPV-negative HNSCC/OPSCC carries inferior prognosis relative to HPV-positive disease | https://doi.org/10.1002/jmv.29746 |
Table: This table summarizes key outcome evidence for HPV-negative HNSCC/OPSCC, including population-level mortality differences, prognostic biomarkers, and biologically distinct prognostic subgroups. It is useful for quickly identifying where HPV-negative disease has worse outcomes and which recent markers may refine risk stratification.
Key quantitative evidence includes: - SEER OPSCC 2010–2015: 5-year head-and-neck cancer-specific mortality 26.9% (HPV−) vs 10.7% (HPV+) (zhang2023causeofdeath pages 1-2). - Translational prognostic biomarkers for HPV− HNSCC: LAMC2 and TGM3 improved outcome prediction beyond nodal status in a validation cohort of 404 patients (waas2024molecularcorrelatesfor pages 1-2). - A favorable HPV− oral cavity SCC subgroup (“CNA-quiet”, 9.1%) with lower Treg density and better survival (muijlwijk2024hallmarksofa pages 1-2).
Across HPV status, core modalities remain surgery, radiotherapy, and systemic therapy, with immune checkpoint inhibitors now standard for recurrent/metastatic disease (krsek2024theroleof pages 14-15, harrington2023pembrolizumabwithor pages 1-2).
For recurrent/metastatic HNSCC, KEYNOTE-048 established pembrolizumab-based first-line therapy stratified by PD-L1 combined positive score (CPS). The updated JCO 2023 report concludes: “With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy” (harrington2023pembrolizumabwithor pages 1-2). This is particularly relevant to HPV− disease because HPV− tumors comprise a major proportion of R/M HNSCC.
| Study (year, journal) | Population | Comparator | Key efficacy results (OS/PFS/HR) | Notes re HPV-negative/p16 status | URL/DOI |
|---|---|---|---|---|---|
| Harrington et al. (2023, J Clin Oncol) | Phase III KEYNOTE-048; recurrent/metastatic HNSCC; n=882; median follow-up 45.0 months (IQR 41.0–49.2) (harrington2023pembrolizumabwithor pages 1-2, harrington2023pembrolizumabwithor pages 2-3) | Pembrolizumab alone or pembrolizumab + chemotherapy vs cetuximab-chemotherapy (EXTREME-like control) (harrington2023pembrolizumabwithor pages 1-2, harrington2023pembrolizumabwithor pages 2-3) | Pembrolizumab monotherapy OS: CPS ≥20: 14.9 vs 10.8 mo, HR 0.61 (95% CI 0.46–0.81); CPS ≥1: 12.3 vs 10.4 mo, HR 0.74 (0.61–0.89); total population: 11.5 vs 10.7 mo, HR 0.81 (0.68–0.97; noninferior). Pembrolizumab + chemotherapy OS: CPS ≥20 HR 0.62 (0.46–0.84); CPS ≥1 HR 0.64 (0.53–0.78); total population HR 0.71 (0.59–0.85). PFS2: improved in key PD-L1 groups; e.g., pembrolizumab CPS ≥20 HR 0.64, CPS ≥1 HR 0.79; pembrolizumab-chemo CPS ≥1 HR 0.66. 4-year follow-up continued to show survival benefit (harrington2023pembrolizumabwithor pages 1-2, harrington2023pembrolizumabwithor pages 2-3) | Trial stratified by p16 status for oropharyngeal cancers; subgroup analyses generally favored pembrolizumab in HPV-negative or smoking-associated disease, making results highly relevant to HPV-negative R/M HNSCC even though efficacy was reported primarily by PD-L1 CPS rather than HPV status (harrington2023pembrolizumabwithor pages 1-2) | https://doi.org/10.1200/JCO.21.02508 |
| Oridate et al. (2024, Int J Clin Oncol) | Japanese KEYNOTE-048 cohort; R/M HNSCC; n=67; pembrolizumab n=23, pembrolizumab-chemo n=25, EXTREME n=19; median follow-up 71.0 months (range 61.2–81.5) (oridate2024firstlinepembrolizumabwith pages 1-2) | Pembrolizumab or pembrolizumab + chemotherapy vs EXTREME (oridate2024firstlinepembrolizumabwith pages 1-2) | 5-year OS, pembrolizumab vs EXTREME: CPS ≥20: 35.7% vs 12.5%, HR 0.38 (95% CI 0.13–1.05); CPS ≥1: 23.8% vs 12.5%, HR 0.70 (0.34–1.45); total: 30.4% vs 10.5%, HR 0.54 (0.27–1.07). Pembrolizumab-chemo vs EXTREME: CPS ≥20: 20.0% vs 14.3%, HR 0.79 (0.27–2.33); CPS ≥1: 10.5% vs 14.3%, HR 1.18 (0.56–2.48); total: 8.0% vs 12.5%, HR 1.11 (0.57–2.16). Earlier analysis cited median OS in CPS ≥20: 28.2 vs 13.3 mo, HR 0.29 (0.09–0.89) (oridate2024firstlinepembrolizumabwith pages 1-2) | Stratified by p16/HPV status for oropharyngeal cancers and PD-L1 22C3 CPS. Small subgroup study, but useful for long-term survivorship benchmarks in HPV-negative–relevant clinical populations (oridate2024firstlinepembrolizumabwith pages 1-2) | https://doi.org/10.1007/s10147-024-02632-x |
| Black et al. (2023, Front Oncol) | Real-world US 1L pembrolizumab in R/M HNSCC; n=646 analyzed (431 pembrolizumab monotherapy; 215 pembrolizumab + chemotherapy); median follow-up 8.3 mo (range 0.0–35.1) (black2023realworldtreatmentpatterns pages 1-2, black2023realworldtreatmentpatterns pages 8-9, black2023realworldtreatmentpatterns pages 3-5, black2023realworldtreatmentpatterns pages 5-6) | Observational comparison of pembrolizumab monotherapy vs pembrolizumab + chemotherapy; no randomized control arm (black2023realworldtreatmentpatterns pages 1-2, black2023realworldtreatmentpatterns pages 3-5) | Pembrolizumab monotherapy: rwOS 12.1 mo (95% CI 9.2–15.1), rwToT 4.2 mo (3.5–4.6), rwTTNT 6.5 mo (5.4–7.4). Pembrolizumab + chemotherapy: rwOS 11.9 mo (9.0–16.0), rwToT 4.9 mo (3.8–5.6), rwTTNT 6.6 mo (5.8–8.3). Survival rates overall: 6 mo 68.0%, 12 mo 50.3%, 24 mo 33.5% (black2023realworldtreatmentpatterns pages 1-2, black2023realworldtreatmentpatterns pages 8-9, black2023realworldtreatmentpatterns pages 3-5) | HPV-positive status and lower ECOG PS were associated with longer rwOS; monotherapy was less likely in HPV-negative tumors. Thus, HPV-negative patients likely represent a poorer-prognosis fraction of the real-world cohort, supporting use of these data as pragmatic context for HPV-negative disease (black2023realworldtreatmentpatterns pages 1-2, black2023realworldtreatmentpatterns pages 3-5, black2023realworldtreatmentpatterns pages 5-6) | https://doi.org/10.3389/fonc.2023.1160144 |
| Cirillo et al. (2024, BMC Cancer) | Single-center retrospective real-world cohort; PD-L1-positive R/M HNSCC treated Feb 2021–Mar 2023; n=92 received pembrolizumab-based 1L therapy (cirillo2024pembrolizumabbasedfirstlinetreatment pages 1-2) | Pembrolizumab monotherapy vs pembrolizumab-based chemoimmunotherapy in routine practice (cirillo2024pembrolizumabbasedfirstlinetreatment pages 1-2) | Median PFS 4 mo; median OS 8 mo overall. Pembrolizumab monotherapy had worse OS than chemoimmunotherapy (log-rank p=.001; HR 2.7). Outcomes improved with CPS ≥20: PFS HR 0.50 (p=.005); OS HR 0.57 (p=.04). ECOG PS2 independently associated with worse PFS and OS. Authors note that, unlike KEYNOTE-048, pembrolizumab regimens did not show statistically significant PFS/ORR improvement in trial reports and that OS curves plateaued in ~20–30% by 4 years (cirillo2024pembrolizumabbasedfirstlinetreatment pages 1-2) | HPV status incorporated in disease framing but not the primary analytic stratifier. Findings are relevant to HPV-negative disease because frailer real-world patients often include poorer-risk HPV-negative tumors and because PD-L1-positive R/M HNSCC practice decisions often mirror those in HPV-negative populations (cirillo2024pembrolizumabbasedfirstlinetreatment pages 1-2) | https://doi.org/10.1186/s12885-024-12155-3 |
Table: This table summarizes pivotal trial and real-world evidence for first-line systemic therapy in recurrent/metastatic HNSCC, emphasizing findings most relevant to HPV-negative disease. It highlights long-term KEYNOTE-048 results, Japanese 5-year follow-up, and real-world pembrolizumab outcomes for practical comparison.
A large US real-world cohort (published 22 May 2023) evaluated first-line pembrolizumab in R/M HNSCC and reported median real-world OS (rwOS) ~12 months in both pembrolizumab monotherapy and pembrolizumab+chemotherapy groups; HPV-positive status was associated with longer rwOS, implying HPV− patients are an adverse-risk subset in practice (black2023realworldtreatmentpatterns pages 1-2, black2023realworldtreatmentpatterns pages 3-5).
A 2024 HPV−-focused therapeutic review emphasizes that durable responses to PD-1 blockade occur in only a subset, and cetuximab responses are “short-lived,” with resistance linked to EGFR–c-MET pathway crosstalk, motivating dual-targeting strategies in HPV− disease (park2024advancedhumanpapillomavirus–negative pages 1-2).
HPV−-restricted (or explicitly p16−/HPV-unrelated) trials in the retrieved ClinicalTrials.gov evidence include neoadjuvant immunoradiotherapy strategies and combined immunotherapy-RT regimens (NCT03624231 chunk 1, NCT03635164 chunk 2, NCT06161545 chunk 1).
| NCT | Population (HPV-/p16-) | Setting | Interventions | Phase | Status | Enrollment | Primary endpoint(s) | Notes |
|---|---|---|---|---|---|---|---|---|
| NCT03624231 | Non-resectable, locally advanced HPV-negative/p16-negative HNSCC; central confirmation required; p16 negativity defined as ≤70% stained cells (NCT03624231 chunk 1, NCT03624231 chunk 2) | Definitive non-surgical local therapy | Arm 1: durvalumab + tremelimumab + radiotherapy; Arm 2: durvalumab + radiotherapy (NCT03624231 chunk 1, NCT03624231 chunk 2) | Phase II (NCT03624231 chunk 1) | Completed (NCT03624231 chunk 1) | 18 | Feasibility (treatment discontinuations due to toxicity) and efficacy including 1-year progression-free survival; also in-field PFS and 1-year distant metastasis-free survival (NCT03624231 chunk 1) | Arm 1 was stopped after interim analyses; QoL endpoints included EORTC QLQ-H&N35 and QLQ-C30 (NCT03624231 chunk 1) |
| NCT03635164 | Resectable HPV- and/or p16-negative intermediate/high-risk HNSCC; excludes p16-positive OPSCC (NCT03635164 chunk 2) | Neoadjuvant preoperative therapy before surgery | Radiotherapy/SBRT with durvalumab prior to surgical resection (NCT03635164 chunk 2) | Phase I/Ib suggested in record text (NCT03635164 chunk 2) | Completed (from trial search result) (NCT03635164 chunk 2) | 21 | Not explicitly reported in retrieved chunk; trial described as neoadjuvant RT + durvalumab with planned FACT H&N v4 QoL collection (NCT03635164 chunk 2) | University of Colorado study; window-style preoperative immunoradiotherapy approach (NCT03635164 chunk 2) |
| NCT03389477 | p16INK4a-negative, HPV-unrelated HNSCC (trial retrieval listing) | Multimodality treatment around chemoradiation | Neoadjuvant palbociclib monotherapy, concurrent chemoradiation, then adjuvant palbociclib monotherapy (trial retrieval listing) | Phase II (trial retrieval listing) | Active, not recruiting (trial retrieval listing) | 26 | Not available in retrieved evidence chunks | Explicitly designed for HPV-unrelated/p16-negative disease; detailed endpoints not available in retrieved chunks (trial retrieval listing) |
| NCT06935188 | HPV-negative, anti-PD-1-resistant recurrent/metastatic HNSCC (trial retrieval listing) | Recurrent/metastatic, post–PD-1 resistance | Dalpiciclib plus cetuximab vs cetuximab alone (trial retrieval listing) | Phase II (trial retrieval listing) | Recruiting (trial retrieval listing) | 98 | Not available in retrieved evidence chunks | Targets CDK4/6 + EGFR strategy in resistant HPV-negative disease; detailed endpoints not available in retrieved chunks (trial retrieval listing) |
| NCT05879484 | PD-L1-positive, HPV-negative recurrent/metastatic HNSCC in phase II; phase Ib included broader SCC populations including HPV-positive and HPV-negative patients (NCT05879484 chunk 1) | Front-line recurrent/metastatic systemic therapy | Pembrolizumab + valemetostat (EZH1/2 dual inhibitor) (NCT05879484 chunk 1) | Phase Ib/II (NCT05879484 chunk 1) | Withdrawn (NCT05879484 chunk 1) | 0 | Phase II disease control rate; Phase Ib safety/RP2D; secondary endpoints included PK, OS, and 6-month PFS (NCT05879484 chunk 1) | Study never opened because CRADA was never executed (NCT05879484 chunk 1) |
| NCT06161545 | Resectable HPV-unrelated HNSCC; for oropharyngeal tumors, p16-negative status specified (NCT06161545 chunk 1) | Neoadjuvant window-of-opportunity, resectable disease | Arm 1: pembrolizumab + N-803; Arm 2: pembrolizumab + N-803 + PD-L1 t-haNK cells (NCT06161545 chunk 1) | Phase II (NCT06161545 chunk 1) | Recruiting (NCT06161545 chunk 1) | 40 | Pathologic tumor response (≤50% viable tumor in resected primary tumor bed) (NCT06161545 chunk 1) | Secondary endpoints include safety, recurrence-free survival, and overall survival at 1 and 2 years (NCT06161545 chunk 1) |
| NCT02358031 | Reference trial in untreated recurrent/metastatic HNSCC; stratified by p16 status for oropharyngeal cancers rather than restricted to HPV-negative disease (harrington2023pembrolizumabwithor pages 1-2, oridate2024firstlinepembrolizumabwith pages 1-2) | First-line recurrent/metastatic benchmark | Pembrolizumab alone or pembrolizumab + chemotherapy vs cetuximab-chemotherapy (harrington2023pembrolizumabwithor pages 1-2, oridate2024firstlinepembrolizumabwith pages 1-2) | Phase III (harrington2023pembrolizumabwithor pages 1-2) | Completed/long-term follow-up reported (harrington2023pembrolizumabwithor pages 1-2, oridate2024firstlinepembrolizumabwith pages 1-2) | 882 overall; Japanese subgroup 67 (harrington2023pembrolizumabwithor pages 1-2, oridate2024firstlinepembrolizumabwith pages 1-2) | Overall survival and progression-free survival by PD-L1 CPS; updated analyses also reported PFS2 (harrington2023pembrolizumabwithor pages 1-2, harrington2023pembrolizumabwithor pages 2-3) | Practice-changing reference standard for R/M HNSCC; highly relevant comparator for HPV-negative populations though not HPV-negative-exclusive (harrington2023pembrolizumabwithor pages 1-2, oridate2024firstlinepembrolizumabwith pages 1-2) |
Table: This table summarizes retrieved ClinicalTrials.gov studies and one pivotal reference trial relevant to HPV-negative or p16-negative HNSCC. It highlights populations, treatment settings, interventions, phases, endpoints, and key operational notes such as interim stopping or withdrawal.
(MAXO IDs are suggested categories; not explicitly enumerated in the retrieved evidence.)
Because tobacco and alcohol account for a large proportion of HNSCC burden and are central in HPV− etiology, risk-factor reduction is the most direct prevention strategy for HPV− disease (huang2023circulatingtumourdna pages 1-2, gribb2023humanpapillomavirus pages 1-3).
A prevention-oriented review explicitly states: “The main risk factors for oropharyngeal SCCa have been multi-factorial, including tobacco and alcohol use” (published April 2023) (gribb2023humanpapillomavirus pages 1-3).
HPV vaccination is the primary prevention strategy for HPV-associated OPSCC and may alter relative proportions of HPV− vs HPV+ OPSCC over time.
A 2023 public policy review reports vaccine efficacy against oral HPV infection of 88–93%, and notes that as of 2022, 122/195 (63%) WHO member states had national HPV vaccination programs, with 41/122 (34%) gender-neutral coverage (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3). A 2024 Nature Reviews Clinical Oncology review notes HPV is attributed to 31% of oropharyngeal cancers worldwide and that vaccination will likely prevent HPV-associated cancers beyond cervical cancer (malagon2024epidemiologyofhpvassociated pages 1-4).
No naturally occurring HPV− HNSCC analogue in non-human species was identified in the retrieved evidence.
Preclinical work in HPV− HNSCC relies on complementary in vitro and in vivo model classes, with 4NQO carcinogen models, PDX, and GEMMs/transposon systems being particularly prominent for carcinogen-associated biology.
| Model type | What it captures (strengths) | Key limitations | Typical use-cases |
|---|---|---|---|
| Cell lines / 2D cultures | Inexpensive, fast, easy to maintain and genetically manipulate; useful for mechanistic studies, pathway perturbation, and high-throughput drug screening; some patient-derived short-term cultures retain features of source tumors better than long-passaged lines (chaves2023preclinicalmodelsin pages 3-4, chaves2023preclinicalmodelsin pages 2-3, tinhofer2020preclinicalmodelsof pages 4-5) | Poorly recapitulate native histology and tumor microenvironment; prone to clonal selection, genomic instability, and drift from original tumors; limited immune/stromal context (chaves2023preclinicalmodelsin pages 3-4, chaves2023preclinicalmodelsin pages 2-3, tinhofer2020preclinicalmodelsof pages 4-5) | Rapid target validation, signaling studies, CRISPR/RNAi perturbation, initial drug sensitivity and resistance screens (chaves2023preclinicalmodelsin pages 3-4, tinhofer2020preclinicalmodelsof pages 4-5) |
| Spheroids / organoids (3D) | Better preserve 3D architecture, intratumoral heterogeneity, and diffusion barriers; can model slower proliferation, reduced drug penetration, and increased treatment resistance; patient-derived organoids can retain genomic and histologic characteristics of parent tumors (chaves2023preclinicalmodelsin pages 3-4, chaves2023preclinicalmodelsin pages 2-3, tinhofer2020preclinicalmodelsof pages 4-5) | Technically more complex; still being standardized; time- and cost-intensive; extracellular matrix dependence and incomplete immune/stromal representation unless specifically reconstituted (chaves2023preclinicalmodelsin pages 3-4, tinhofer2020preclinicalmodelsof pages 4-5) | Ex vivo drug testing, personalized therapy assessment, plasticity/EMT studies, modeling cisplatin resistance and heterogeneous treatment response (chaves2023preclinicalmodelsin pages 3-4, tinhofer2020preclinicalmodelsof pages 4-5) |
| Microfluidic / organotypic / host–microbe co-culture models | Preserve tissue architecture and enable study of epithelial-stromal-immune and microbiome interactions under controlled conditions; useful for dissecting host–bacterial interactions relevant to oral/HPV-negative carcinogenesis (chaves2023preclinicalmodelsin pages 3-4, chaves2023preclinicalmodelsin pages 2-3, tasoulas2023geneticallyengineeredmouse pages 5-7) | Expensive, labor-intensive, lower throughput; technical setup can limit widespread adoption; often lack full systemic physiology (chaves2023preclinicalmodelsin pages 3-4, chaves2023preclinicalmodelsin pages 2-3) | Tumor–microenvironment crosstalk, microbiome-cancer interaction studies, invasion assays, testing local immune or stromal modulation (chaves2023preclinicalmodelsin pages 3-4, tasoulas2023geneticallyengineeredmouse pages 5-7) |
| Patient-derived xenografts (PDX) | Retain tumor histology, genetics, and heterogeneity; often correlate with aggressiveness; useful bridge between patient tumors and in vivo therapeutic testing; can support derivation of secondary cultures/organoids (chaves2023preclinicalmodelsin pages 2-3, tinhofer2020preclinicalmodelsof pages 4-5, zohud2023towardssystemgenetics pages 2-3) | Time-consuming and expensive; mouse microenvironment replaces human stroma over time; standard PDX lack intact human immunity, limiting immunotherapy studies; prolonged passaging risks divergence (chaves2023preclinicalmodelsin pages 2-3, tinhofer2020preclinicalmodelsof pages 4-5, zohud2023towardssystemgenetics pages 2-3) | Biomarker discovery, in vivo efficacy testing, resistance modeling, translational validation of poor-prognosis molecular phenotypes in HPV-negative HNSCC (chaves2023preclinicalmodelsin pages 2-3, waas2024molecularcorrelatesfor pages 1-2, zohud2023towardssystemgenetics pages 2-3) |
| 4NQO carcinogen mouse model | Immunocompetent carcinogen-induced model that closely resembles multistep oral carcinogenesis and tobacco-associated disease; preserves genetic heterogeneity and native immune context; useful for initiation-to-progression studies and immunotherapy development (tinhofer2020preclinicalmodelsof pages 4-5, chaves2023preclinicalmodelsin pages 3-4, tasoulas2023geneticallyengineeredmouse pages 5-7) | Long latency (often many months, with metastasis studies taking longer); tumor onset can be variable; strongest for oral cavity/tongue rather than all head and neck subsites (tinhofer2020preclinicalmodelsof pages 4-5, chaves2023preclinicalmodelsin pages 3-4, tasoulas2023geneticallyengineeredmouse pages 5-7) | Studying carcinogenesis, premalignant-to-malignant transition, immune suppression, chemoprevention, and testing therapies in tobacco-mimetic HPV-negative settings (tinhofer2020preclinicalmodelsof pages 4-5, chaves2023preclinicalmodelsin pages 3-4) |
| GEMMs / transposon-based mouse models | Allow causal testing of specific drivers in controlled genetic backgrounds; can recapitulate stromal and immune microenvironments because tumors arise in situ; luciferase/reporters can enable longitudinal tracking; transposon systems accelerate identification of cooperating genes (tasoulas2023geneticallyengineeredmouse pages 5-7, tinhofer2020preclinicalmodelsof pages 4-5) | Often costly and slow; low incidence or incomplete penetrance in some models; some require added carcinogen (e.g., 4NQO) to produce frank malignancy; many available models are not fully representative of human HPV-negative oropharyngeal disease (tasoulas2023geneticallyengineeredmouse pages 5-7, tinhofer2020preclinicalmodelsof pages 4-5, zohud2023towardssystemgenetics pages 2-3) | Functional validation of TP53/CDKN2A/FAT1/PIK3CA-type drivers, lineage and progression studies, immune-oncology experiments, modeling initiation and metastatic spread in vivo (tasoulas2023geneticallyengineeredmouse pages 5-7, tinhofer2020preclinicalmodelsof pages 4-5) |
Table: This table summarizes the main preclinical systems used to study HPV-negative head and neck squamous cell carcinoma, highlighting what each model captures, its limitations, and its best-fit applications. It is useful for matching a research question to the most appropriate model platform.
Key expert consensus points: - 4NQO: immunocompetent and resembles multistep oral carcinogenesis but with long latency (tinhofer2020preclinicalmodelsof pages 4-5, chaves2023preclinicalmodelsin pages 3-4). - PDX: preserves heterogeneity but lacks human immunity and is resource intensive (chaves2023preclinicalmodelsin pages 2-3, zohud2023towardssystemgenetics pages 2-3). - GEMMs: enable causal tests of TP53/CDKN2A-type drivers; some need 4NQO to achieve frank malignancy (tasoulas2023geneticallyengineeredmouse pages 5-7).
1) HPV− molecular stratification is maturing: HPV− HNSCC is not a single entity; transcriptomic subtype immune landscapes (classical/basal/mesenchymal/atypical) and CNA-quiet genomic subclasses support precision stratification and trial design (xie2024immunelandscapein pages 2-3, muijlwijk2024hallmarksofa pages 1-2).
2) Immune checkpoint therapy is standard but insufficient: KEYNOTE-048 continues to support pembrolizumab-based first-line R/M therapy with durable benefit in subsets, while HPV−-specific reviews emphasize a noninflamed/hypoxic TME and tumor suppressor loss contributing to resistance (harrington2023pembrolizumabwithor pages 1-2, park2024advancedhumanpapillomavirus–negative pages 1-2).
3) Diagnostics are shifting toward multimodal confirmation: Recognition of p16 discordance and false positives supports confirmatory HPV nucleic-acid testing and/or combined p16+p53 IHC approaches to classify HPV-associated vs HPV-independent tumors, especially where treatment decisions depend on HPV status (pakkanen2024simultaneousp53and pages 5-6, tran2024advancesinhuman pages 6-7, gallus2023accuracyofp16 media 97554451).
References
(krsek2024theroleof pages 14-15): Antea Krsek, Lara Baticic, Vlatka Sotosek, and Tamara Braut. The role of biomarkers in hpv-positive head and neck squamous cell carcinoma: towards precision medicine. Diagnostics, 14:1448, Jul 2024. URL: https://doi.org/10.3390/diagnostics14131448, doi:10.3390/diagnostics14131448. This article has 26 citations.
(tasoulas2023geneticallyengineeredmouse pages 1-2): Jason Tasoulas, Sonal Srivastava, Xiaonan Xu, Valentina Tarasova, Anastasios Maniakas, Florian A. Karreth, and Antonio L. Amelio. Genetically engineered mouse models of head and neck cancers. Oncogene, 42:2593-2609, Jul 2023. URL: https://doi.org/10.1038/s41388-023-02783-7, doi:10.1038/s41388-023-02783-7. This article has 15 citations and is from a domain leading peer-reviewed journal.
(xie2024immunelandscapein pages 1-2): Mengyu Xie, Ritu Chaudhary, Robbert J. C. Slebos, Kyubum Lee, Feifei Song, Maria I. Poole, Dirk S. Hoening, Leenil C. Noel, Juan C. Hernandez‐Prera, Jose R. Conejo‐Garcia, Christine H. Chung, and Aik Choon Tan. Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancer. Molecular Carcinogenesis, 63:120-135, Sep 2024. URL: https://doi.org/10.1002/mc.23640, doi:10.1002/mc.23640. This article has 3 citations and is from a peer-reviewed journal.
(pakkanen2024simultaneousp53and pages 1-2): Pihla Pakkanen, Antti Silvoniemi, Katri Aro, Leif Bäck, Heikki Irjala, Leena-Maija Aaltonen, Jaana Hagström, Caj Haglund, Jukka Laine, Heikki Minn, and Jutta Huvila. Simultaneous p53 and p16 immunostaining for molecular subclassification of head and neck squamous cell carcinomas. Head and Neck Pathology, Aug 2024. URL: https://doi.org/10.1007/s12105-024-01680-z, doi:10.1007/s12105-024-01680-z. This article has 6 citations and is from a peer-reviewed journal.
(gallus2023accuracyofp16 pages 1-2): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(tran2024advancesinhuman pages 6-7): Ngoc Ha Tran, Dayna Sais, and Nham Tran. Advances in human papillomavirus detection and molecular understanding in head and neck cancers: implications for clinical management. Journal of Medical Virology, Jun 2024. URL: https://doi.org/10.1002/jmv.29746, doi:10.1002/jmv.29746. This article has 27 citations and is from a peer-reviewed journal.
(gallus2023accuracyofp16 pages 4-5): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(gallus2023accuracyofp16 pages 2-4): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(park2024advancedhumanpapillomavirus–negative pages 1-2): Robin Park and Christine H. Chung. Advanced human papillomavirus–negative head and neck squamous cell carcinoma: unmet need and emerging therapies. Molecular Cancer Therapeutics, 23:1717-1730, Sep 2024. URL: https://doi.org/10.1158/1535-7163.mct-24-0281, doi:10.1158/1535-7163.mct-24-0281. This article has 9 citations and is from a peer-reviewed journal.
(harrington2023pembrolizumabwithor pages 1-2): Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Irene Brana, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G.M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, and Danny Rischin. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase iii keynote-048 study. Journal of Clinical Oncology, 41:790-802, Feb 2023. URL: https://doi.org/10.1200/jco.21.02508, doi:10.1200/jco.21.02508. This article has 541 citations and is from a highest quality peer-reviewed journal.
(zhang2023causeofdeath pages 1-2): Dong-Dong Zhang, Min Lei, Yue Wang, Pei-Ji Zeng, Yong-Jun Hong, and Cheng-Fu Cai. Cause of death in patients with oropharyngeal carcinoma by human papillomavirus status: comparative data analysis. JMIR Public Health and Surveillance, 9:e47579, Aug 2023. URL: https://doi.org/10.2196/47579, doi:10.2196/47579. This article has 6 citations and is from a peer-reviewed journal.
(waas2024molecularcorrelatesfor pages 1-2): Matthew Waas, Christina Karamboulas, Benson Z. Wu, Shahbaz Khan, Stephanie Poon, Jalna Meens, Meinusha Govindarajan, Amanda Khoo, Salvador Mejia-Guerrero, Annie Ha, Lydia Y. Liu, Kevin C. J. Nixon, Joseph Walton, Scott V. Bratman, Shao Hui Huang, David Goldstein, Federico Gaiti, Laurie Ailles, and Thomas Kislinger. Molecular correlates for hpv-negative head and neck cancer engraftment prognosticate patient outcomes. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-55203-z, doi:10.1038/s41467-024-55203-z. This article has 12 citations and is from a highest quality peer-reviewed journal.
(huang2023circulatingtumourdna pages 1-2): Xiaomin Huang, Pascal H. G. Duijf, Sharath Sriram, Ganganath Perera, Sarju Vasani, Lizbeth Kenny, Paul Leo, and Chamindie Punyadeera. Circulating tumour dna alterations: emerging biomarker in head and neck squamous cell carcinoma. Journal of Biomedical Science, Aug 2023. URL: https://doi.org/10.1186/s12929-023-00953-z, doi:10.1186/s12929-023-00953-z. This article has 36 citations and is from a domain leading peer-reviewed journal.
(gribb2023humanpapillomavirus pages 1-3): Jacob P. Gribb, John H. Wheelock, and Etern S. Park. Human papilloma virus (hpv) and the current state of oropharyngeal cancer prevention and treatment. Delaware Journal of Public Health, 9:26-28, Apr 2023. URL: https://doi.org/10.32481/djph.2023.04.008, doi:10.32481/djph.2023.04.008. This article has 42 citations.
(ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3): Sifon Ndon, Amritpal Singh, Patrick K. Ha, Joyce Aswani, Jason Ying-Kuen Chan, and Mary Jue Xu. Human papillomavirus-associated oropharyngeal cancer: global epidemiology and public policy implications. Cancers, 15:4080, Aug 2023. URL: https://doi.org/10.3390/cancers15164080, doi:10.3390/cancers15164080. This article has 58 citations.
(malagon2024epidemiologyofhpvassociated pages 1-4): Talía Malagón, Eduardo L. Franco, Romina Tejada, and Salvatore Vaccarella. Epidemiology of hpv-associated cancers past, present and future: towards prevention and elimination. Nature Reviews Clinical Oncology, 21:522-538, May 2024. URL: https://doi.org/10.1038/s41571-024-00904-z, doi:10.1038/s41571-024-00904-z. This article has 137 citations and is from a domain leading peer-reviewed journal.
(huang2023circulatingtumourdna pages 4-6): Xiaomin Huang, Pascal H. G. Duijf, Sharath Sriram, Ganganath Perera, Sarju Vasani, Lizbeth Kenny, Paul Leo, and Chamindie Punyadeera. Circulating tumour dna alterations: emerging biomarker in head and neck squamous cell carcinoma. Journal of Biomedical Science, Aug 2023. URL: https://doi.org/10.1186/s12929-023-00953-z, doi:10.1186/s12929-023-00953-z. This article has 36 citations and is from a domain leading peer-reviewed journal.
(sharma2024dysphagiavoiceproblems pages 2-3): Vaishali Sharma, Jisa George T, R Velmurugan, and Rajesh Pasricha. Dysphagia, voice problems and health related quality of life among head and neck cancer survivors. Journal of Caring Sciences, 13:207-213, Aug 2024. URL: https://doi.org/10.34172/jcs.33282, doi:10.34172/jcs.33282. This article has 2 citations.
(sharma2024dysphagiavoiceproblems pages 1-2): Vaishali Sharma, Jisa George T, R Velmurugan, and Rajesh Pasricha. Dysphagia, voice problems and health related quality of life among head and neck cancer survivors. Journal of Caring Sciences, 13:207-213, Aug 2024. URL: https://doi.org/10.34172/jcs.33282, doi:10.34172/jcs.33282. This article has 2 citations.
(filippini2024healthrelatedqualityof pages 1-2): Daria Maria Filippini, Francesca Carosi, Olimpia Panepinto, Giacomo Neri, Elisabetta Nobili, Nastassja Tober, Raffaele Giusti, and Massimo Di Maio. Health-related quality of life assessment in head and neck cancer: a systematic review of phase ii and iii clinical trials. Heliyon, 10:e40671, Dec 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e40671, doi:10.1016/j.heliyon.2024.e40671. This article has 3 citations.
(muijlwijk2024hallmarksofa pages 1-2): Tara Muijlwijk, Irene H. Nauta, Anabel van der Lee, Kari J. T. Grünewald, Arjen Brink, Sonja H. Ganzevles, Robert J. Baatenburg de Jong, Lilit Atanesyan, Suvi Savola, Mark A. van de Wiel, Laura A. N. Peferoen, Elisabeth Bloemena, Rieneke van de Ven, C. René Leemans, Jos B. Poell, and Ruud H. Brakenhoff. Hallmarks of a genomically distinct subclass of head and neck cancer. Nature Communications, Oct 2024. URL: https://doi.org/10.1038/s41467-024-53390-3, doi:10.1038/s41467-024-53390-3. This article has 18 citations and is from a highest quality peer-reviewed journal.
(xie2024immunelandscapein pages 2-3): Mengyu Xie, Ritu Chaudhary, Robbert J. C. Slebos, Kyubum Lee, Feifei Song, Maria I. Poole, Dirk S. Hoening, Leenil C. Noel, Juan C. Hernandez‐Prera, Jose R. Conejo‐Garcia, Christine H. Chung, and Aik Choon Tan. Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancer. Molecular Carcinogenesis, 63:120-135, Sep 2024. URL: https://doi.org/10.1002/mc.23640, doi:10.1002/mc.23640. This article has 3 citations and is from a peer-reviewed journal.
(zhou2024globalburdenof pages 1-2): Tianjiao Zhou, Weijun Huang, Xiaoting Wang, Jingyu Zhang, Enhui Zhou, Yixing Tu, Jianyin Zou, Kaiming Su, Hongliang Yi, and Shankai Yin. Global burden of head and neck cancers from 1990 to 2019. iScience, 27:109282, Mar 2024. URL: https://doi.org/10.1016/j.isci.2024.109282, doi:10.1016/j.isci.2024.109282. This article has 63 citations and is from a peer-reviewed journal.
(kim2024aseerbasedanalysis pages 1-2): Su Il Kim, Jung Woo Lee, Young-Gyu Eun, and Young Chan Lee. A seer-based analysis of trends in hpv-associated oropharyngeal squamous cell carcinoma. Infectious Agents and Cancer, Jun 2024. URL: https://doi.org/10.1186/s13027-024-00592-5, doi:10.1186/s13027-024-00592-5. This article has 12 citations and is from a peer-reviewed journal.
(tran2024advancesinhuman pages 6-6): Ngoc Ha Tran, Dayna Sais, and Nham Tran. Advances in human papillomavirus detection and molecular understanding in head and neck cancers: implications for clinical management. Journal of Medical Virology, Jun 2024. URL: https://doi.org/10.1002/jmv.29746, doi:10.1002/jmv.29746. This article has 27 citations and is from a peer-reviewed journal.
(gallus2023accuracyofp16 media 97554451): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(gallus2023accuracyofp16 media 6b48023a): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(gallus2023accuracyofp16 media 4f7617b0): Roberto Gallus, Irene H Nauta, Linda Marklund, Davide Rizzo, Claudia Crescio, Luca Mureddu, Paolo Tropiano, Giovanni Delogu, and Francesco Bussu. Accuracy of p16 ihc in classifying hpv-driven opscc in different populations. Cancers, 15:656, Jan 2023. URL: https://doi.org/10.3390/cancers15030656, doi:10.3390/cancers15030656. This article has 35 citations.
(pakkanen2024simultaneousp53and pages 5-6): Pihla Pakkanen, Antti Silvoniemi, Katri Aro, Leif Bäck, Heikki Irjala, Leena-Maija Aaltonen, Jaana Hagström, Caj Haglund, Jukka Laine, Heikki Minn, and Jutta Huvila. Simultaneous p53 and p16 immunostaining for molecular subclassification of head and neck squamous cell carcinomas. Head and Neck Pathology, Aug 2024. URL: https://doi.org/10.1007/s12105-024-01680-z, doi:10.1007/s12105-024-01680-z. This article has 6 citations and is from a peer-reviewed journal.
(tran2024advancesinhuman pages 2-3): Ngoc Ha Tran, Dayna Sais, and Nham Tran. Advances in human papillomavirus detection and molecular understanding in head and neck cancers: implications for clinical management. Journal of Medical Virology, Jun 2024. URL: https://doi.org/10.1002/jmv.29746, doi:10.1002/jmv.29746. This article has 27 citations and is from a peer-reviewed journal.
(tran2024advancesinhuman pages 2-2): Ngoc Ha Tran, Dayna Sais, and Nham Tran. Advances in human papillomavirus detection and molecular understanding in head and neck cancers: implications for clinical management. Journal of Medical Virology, Jun 2024. URL: https://doi.org/10.1002/jmv.29746, doi:10.1002/jmv.29746. This article has 27 citations and is from a peer-reviewed journal.
(harrington2023pembrolizumabwithor pages 2-3): Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Irene Brana, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G.M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, and Danny Rischin. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase iii keynote-048 study. Journal of Clinical Oncology, 41:790-802, Feb 2023. URL: https://doi.org/10.1200/jco.21.02508, doi:10.1200/jco.21.02508. This article has 541 citations and is from a highest quality peer-reviewed journal.
(oridate2024firstlinepembrolizumabwith pages 1-2): Nobuhiko Oridate, Shunji Takahashi, Kaoru Tanaka, Yasushi Shimizu, Yasushi Fujimoto, Koji Matsumoto, Tomoya Yokota, Tomoko Yamazaki, Masanobu Takahashi, Tsutomu Ueda, Nobuhiro Hanai, Hironori Yamaguchi, Hiroki Hara, Tomokazu Yoshizaki, Ryuji Yasumatsu, Masahiro Nakayama, Kiyoto Shiga, Takashi Fujii, Kenji Mitsugi, Kenichi Takahashi, Nijiro Nohata, Burak Gumuscu, Nati Lerman, and Makoto Tahara. First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the japanese population of keynote‑048. International Journal of Clinical Oncology, 29:1825-1839, Oct 2024. URL: https://doi.org/10.1007/s10147-024-02632-x, doi:10.1007/s10147-024-02632-x. This article has 9 citations and is from a peer-reviewed journal.
(black2023realworldtreatmentpatterns pages 1-2): Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, and Gleicy M. Hair. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1160144, doi:10.3389/fonc.2023.1160144. This article has 22 citations.
(black2023realworldtreatmentpatterns pages 8-9): Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, and Gleicy M. Hair. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1160144, doi:10.3389/fonc.2023.1160144. This article has 22 citations.
(black2023realworldtreatmentpatterns pages 3-5): Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, and Gleicy M. Hair. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1160144, doi:10.3389/fonc.2023.1160144. This article has 22 citations.
(black2023realworldtreatmentpatterns pages 5-6): Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, and Gleicy M. Hair. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1160144, doi:10.3389/fonc.2023.1160144. This article has 22 citations.
(cirillo2024pembrolizumabbasedfirstlinetreatment pages 1-2): Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, and Andrea Botticelli. Pembrolizumab-based first-line treatment for pd-l1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis. BMC Cancer, Apr 2024. URL: https://doi.org/10.1186/s12885-024-12155-3, doi:10.1186/s12885-024-12155-3. This article has 11 citations and is from a peer-reviewed journal.
(NCT03624231 chunk 1): Ulrich Keilholz. Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC. Ulrich Keilholz. 2018. ClinicalTrials.gov Identifier: NCT03624231
(NCT03635164 chunk 2): Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma. University of Colorado, Denver. 2018. ClinicalTrials.gov Identifier: NCT03635164
(NCT06161545 chunk 1): Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma. National Cancer Institute (NCI). 2025. ClinicalTrials.gov Identifier: NCT06161545
(NCT03624231 chunk 2): Ulrich Keilholz. Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC. Ulrich Keilholz. 2018. ClinicalTrials.gov Identifier: NCT03624231
(NCT05879484 chunk 1): Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS. National Cancer Institute (NCI). 2025. ClinicalTrials.gov Identifier: NCT05879484
(chaves2023preclinicalmodelsin pages 3-4): Patricia Chaves, María Garrido, Javier Oliver, Elisabeth Pérez-Ruiz, Isabel Barragan, and Antonio Rueda-Domínguez. Preclinical models in head and neck squamous cell carcinoma. British Journal of Cancer, 128:1819-1827, Feb 2023. URL: https://doi.org/10.1038/s41416-023-02186-1, doi:10.1038/s41416-023-02186-1. This article has 70 citations and is from a domain leading peer-reviewed journal.
(chaves2023preclinicalmodelsin pages 2-3): Patricia Chaves, María Garrido, Javier Oliver, Elisabeth Pérez-Ruiz, Isabel Barragan, and Antonio Rueda-Domínguez. Preclinical models in head and neck squamous cell carcinoma. British Journal of Cancer, 128:1819-1827, Feb 2023. URL: https://doi.org/10.1038/s41416-023-02186-1, doi:10.1038/s41416-023-02186-1. This article has 70 citations and is from a domain leading peer-reviewed journal.
(tinhofer2020preclinicalmodelsof pages 4-5): Ingeborg Tinhofer, Diana Braunholz, and Konrad Klinghammer. Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers of the Head & Neck, Jul 2020. URL: https://doi.org/10.1186/s41199-020-00056-4, doi:10.1186/s41199-020-00056-4. This article has 67 citations.
(tasoulas2023geneticallyengineeredmouse pages 5-7): Jason Tasoulas, Sonal Srivastava, Xiaonan Xu, Valentina Tarasova, Anastasios Maniakas, Florian A. Karreth, and Antonio L. Amelio. Genetically engineered mouse models of head and neck cancers. Oncogene, 42:2593-2609, Jul 2023. URL: https://doi.org/10.1038/s41388-023-02783-7, doi:10.1038/s41388-023-02783-7. This article has 15 citations and is from a domain leading peer-reviewed journal.
(zohud2023towardssystemgenetics pages 2-3): Osayd Zohud, Iqbal M. Lone, Aysar Nashef, and Fuad A. Iraqi. Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data. Animal Models and Experimental Medicine, 6:537-558, Dec 2023. URL: https://doi.org/10.1002/ame2.12367, doi:10.1002/ame2.12367. This article has 11 citations.